The SeriousTraders Newsletter If you are Serious about Trading, become a SeriousTrader!™

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

Investment Considerations LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations. LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management … Continue reading “LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)”

View Profile